Jane Street Group LLC Acquires 248,805 Shares of Exscientia plc (NASDAQ:EXAI)

Jane Street Group LLC increased its stake in Exscientia plc (NASDAQ:EXAI) by 601.7% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 290,154 shares of the company’s stock after buying an additional 248,805 shares during the period. Jane Street Group LLC owned 0.23% of Exscientia worth $1,416,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in EXAI. China Universal Asset Management Co. Ltd. boosted its holdings in Exscientia by 66.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,576 shares of the company’s stock worth $47,000 after acquiring an additional 3,821 shares in the last quarter. Vanguard Personalized Indexing Management LLC bought a new stake in Exscientia in the 2nd quarter worth approximately $54,000. International Assets Investment Management LLC purchased a new position in Exscientia in the third quarter worth about $77,000. Federated Hermes Inc. bought a new stake in shares of Exscientia during the 2nd quarter valued at about $115,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Exscientia during the 2nd quarter valued at about $256,000. Institutional investors own 41.58% of the company’s stock.

Exscientia Price Performance

Shares of NASDAQ:EXAI opened at $4.84 on Friday. The company has a quick ratio of 4.54, a current ratio of 4.54 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $632.93 million, a PE ratio of -3.21 and a beta of 0.83. The firm’s 50 day moving average price is $4.97 and its 200-day moving average price is $5.10. Exscientia plc has a twelve month low of $3.80 and a twelve month high of $7.91.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.